Cancer
Research reports from University of Oxford provide new insights into cancer
Published in Hematology Week, July 20th, 2009
According to recent research from Oxford, the United Kingdom, "Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled with 5-fold decreased anthracycline toxicity in chemotherapy-refractory patients. Here we report phase H studies using a similar material (FCE28068) in patients with breast (n=17), non-small cell lung (NSCLC, n=29) and colorectal (n=16) cancer."
"Up to 8 courses of PK1 (280 mg/m(2) doxorubicin-equivalent) were given i.v., together with I-123-labelled imaging analogue. Toxicities were tolerable, with grade 3 neutropenia more prominent in patients with breast cancer (4/17, 23.5%...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2009-07-20)
More Articles from Hematology Week
- BioMed Central
A rush of blood to the head -- anger increases blood flow - Columbia University Medical Center
Genetic factors implicated in survival gap for breast, ovarian or prostate cancer - Elsevier Health Sciences
Society for Vascular Nursing releases patient care guideline - Georgetown University Medical Center
GUMC discovery highlights new direction for drug discovery - Gladstone Institutes
Gladstone scientists identify genetic factors that hold promise for treatment of vascular diseases - Lifespan
Researchers find possible environmental causes for Alzheimer's, diabetes - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
